Abstract
Purpose: This retrospective, single-center study evaluated radiofrequency (RF) ablation for pulmonary metastases of sarcoma. Materials and methods: Forty-six patients with sarcoma (144 pulmonary metastases) underwent 88 RF ablation sessions. Data regarding local tumor progression, efficacy, procedural adverse events (AEs; National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0), overall survival (OS), and OS-associated prognostic factors were retrospectively evaluated using univariate analyses. Results: Local progression occurred in 22 of 144 tumors (15.3%). Primary and secondary efficacy rates were 83.5 and 90.0% at 1 year and 76.3 and 81.4% at 2 years, respectively. Seventy-three grade 1 AEs, 33 grade 2 AEs, and no grade ≥ 3 AEs were observed. Twenty-eight patients (60.9%) remained alive and 18 died, yielding 1-, 2-, and 3-year OS rates of 80.6, 70.1, and 47.1% (median survival time, 31.7 months). Univariate analysis revealed extrapulmonary metastasis (P = 0.005), noncurative RF ablation (P = 0.009), and a post-RF ablation disease-free interval of ≤12 months (P = 0.015) as significant negative prognostic factors. Conclusion: RF ablation is safe, offers good local control, and may be a viable treatment option for pulmonary metastasis of sarcoma.
| Original language | English |
|---|---|
| Pages (from-to) | 61-67 |
| Number of pages | 7 |
| Journal | Japanese Journal of Radiology |
| Volume | 35 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 1 2017 |
Fingerprint
Keywords
- Lung metastasis
- Radiofrequency ablation
- Sarcoma
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
Cite this
Radiofrequency ablation of pulmonary metastases from sarcoma : single-center retrospective evaluation of 46 patients. / Sato, Takuya; Iguchi, Toshihiro; Hiraki, Takao; Gobara, Hideo; Fujiwara, Hiroyasu; Sakurai, Jun; Matsui, Yusuke; Mitsuhashi, Toshiharu; Sou, Junichi; Toyooka, Shinichi; Kanazawa, Susumu.
In: Japanese Journal of Radiology, Vol. 35, No. 2, 01.02.2017, p. 61-67.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Radiofrequency ablation of pulmonary metastases from sarcoma
T2 - single-center retrospective evaluation of 46 patients
AU - Sato, Takuya
AU - Iguchi, Toshihiro
AU - Hiraki, Takao
AU - Gobara, Hideo
AU - Fujiwara, Hiroyasu
AU - Sakurai, Jun
AU - Matsui, Yusuke
AU - Mitsuhashi, Toshiharu
AU - Sou, Junichi
AU - Toyooka, Shinichi
AU - Kanazawa, Susumu
PY - 2017/2/1
Y1 - 2017/2/1
N2 - Purpose: This retrospective, single-center study evaluated radiofrequency (RF) ablation for pulmonary metastases of sarcoma. Materials and methods: Forty-six patients with sarcoma (144 pulmonary metastases) underwent 88 RF ablation sessions. Data regarding local tumor progression, efficacy, procedural adverse events (AEs; National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0), overall survival (OS), and OS-associated prognostic factors were retrospectively evaluated using univariate analyses. Results: Local progression occurred in 22 of 144 tumors (15.3%). Primary and secondary efficacy rates were 83.5 and 90.0% at 1 year and 76.3 and 81.4% at 2 years, respectively. Seventy-three grade 1 AEs, 33 grade 2 AEs, and no grade ≥ 3 AEs were observed. Twenty-eight patients (60.9%) remained alive and 18 died, yielding 1-, 2-, and 3-year OS rates of 80.6, 70.1, and 47.1% (median survival time, 31.7 months). Univariate analysis revealed extrapulmonary metastasis (P = 0.005), noncurative RF ablation (P = 0.009), and a post-RF ablation disease-free interval of ≤12 months (P = 0.015) as significant negative prognostic factors. Conclusion: RF ablation is safe, offers good local control, and may be a viable treatment option for pulmonary metastasis of sarcoma.
AB - Purpose: This retrospective, single-center study evaluated radiofrequency (RF) ablation for pulmonary metastases of sarcoma. Materials and methods: Forty-six patients with sarcoma (144 pulmonary metastases) underwent 88 RF ablation sessions. Data regarding local tumor progression, efficacy, procedural adverse events (AEs; National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0), overall survival (OS), and OS-associated prognostic factors were retrospectively evaluated using univariate analyses. Results: Local progression occurred in 22 of 144 tumors (15.3%). Primary and secondary efficacy rates were 83.5 and 90.0% at 1 year and 76.3 and 81.4% at 2 years, respectively. Seventy-three grade 1 AEs, 33 grade 2 AEs, and no grade ≥ 3 AEs were observed. Twenty-eight patients (60.9%) remained alive and 18 died, yielding 1-, 2-, and 3-year OS rates of 80.6, 70.1, and 47.1% (median survival time, 31.7 months). Univariate analysis revealed extrapulmonary metastasis (P = 0.005), noncurative RF ablation (P = 0.009), and a post-RF ablation disease-free interval of ≤12 months (P = 0.015) as significant negative prognostic factors. Conclusion: RF ablation is safe, offers good local control, and may be a viable treatment option for pulmonary metastasis of sarcoma.
KW - Lung metastasis
KW - Radiofrequency ablation
KW - Sarcoma
UR - http://www.scopus.com/inward/record.url?scp=84995745226&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84995745226&partnerID=8YFLogxK
U2 - 10.1007/s11604-016-0601-z
DO - 10.1007/s11604-016-0601-z
M3 - Article
VL - 35
SP - 61
EP - 67
JO - Japanese Journal of Radiology
JF - Japanese Journal of Radiology
SN - 1867-1071
IS - 2
ER -